A network meta-analysis of 129,465 patients showed GLP-1RAs reduce cardiovascular death by 13% and stroke by 13%, SGLT2i reduce heart failure hospitalization by 35%, while DPP-4 inhibitors have no cardiovascular benefit and may increase pancreatitis risk.
Zero CV benefit from DPP4iDPP-4 inhibitors showed OR 1.00 for cardiovascular death in high-certainty evidence — no benefit at all — while GLP-1 and SGLT2 drugs save lives
What the researchers found
GLP-1RA: reduced CV death (OR 0.87), all-cause death (OR 0.88), stroke (OR 0.87) — all high-certainty. SGLT2i: reduced CV death (OR 0.82), all-cause death (OR 0.84), HF hospitalization (OR 0.65). DPP4i: no benefit on any CV outcome. DPP4i likely increase pancreatitis (OR 1.63). 129,465 participants, 20 studies.
Why it matters
This definitive comparison helps doctors choose the right diabetes drug for patients with heart disease. DPP-4 inhibitors clearly fall short, while GLP-1 and SGLT2 drugs save lives — with each class excelling at different cardiovascular endpoints.
The numbers in context
GLP-1RA CV mortality OR 0.87; SGLT2i CV mortality OR 0.82; SGLT2i HF hospitalization OR 0.65; DPP4i pancreatitis OR 1.63
How the study worked
Cochrane systematic review and network meta-analysis. 31 studies identified (287 records), 20 pooled (129,465 participants). 6 DPP4i, 7 GLP-1RA, 7 SGLT2i trials. Standard and network meta-analysis. GRADE certainty assessment. Risk of bias evaluation.
Who was studied
Adults with type 2 diabetes and established cardiovascular disease
What this study cannot tell us
No direct head-to-head comparisons between the three drug classes (network meta-analysis uses indirect comparisons). Most participants had established CVD — results may differ in primary prevention. Individual drug-level differences within classes not fully explored.
How to read the evidence
High evidence: Cochrane systematic review and network meta-analysis with GRADE assessment. 129,465 participants across 20 RCTs. Most outcomes graded moderate-to-high certainty.
When this study was published
Published 2021. Additional cardiovascular outcome data has since reinforced the superiority of GLP-1RAs and SGLT2is over DPP4is.
The bigger picture
This meta-analysis reshapes the diabetes drug hierarchy. The clear cardiovascular superiority of GLP-1 and SGLT2 drugs over DPP-4 inhibitors supports guidelines recommending them as preferred second-line agents after metformin, especially in patients with established heart disease.
Questions still open
- Should DPP-4 inhibitors be deprioritized in guidelines given zero cardiovascular benefit?
- Do GLP-1 and SGLT2 drugs provide cardiovascular protection in non-diabetic heart disease patients?
- Would combining GLP-1RA + SGLT2i provide additive cardiovascular protection?
Common questions
Which diabetes drug class is best for heart protection?
Should I switch from a DPP-4 inhibitor?
Read the original research
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
The Cochrane database of systematic reviews, 10(10), CD013650
Citation
Kanie, Takayoshi; Mizuno, Atsushi; Takaoka, Yoshimitsu; Suzuki, Takahiro; Yoneoka, Daisuke; Nishikawa, Yuri; Tam, Wilson Wai San; Morze, Jakub; Rynkiewicz, Andrzej; Xin, Yiqiao; Wu, Olivia; Providencia, Rui; Kwong, Joey Sw. (2021). Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.. The Cochrane database of systematic reviews, 10(10), CD013650. https://doi.org/10.1002/14651858.CD013650.pub2